Tag: M.W:200-300

36725-28-7, 6-(4-Aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one is a pyridazine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

EXAMPLE 16 (R)-5-Methyl-6-[4-(4-oxo-1,4-dihydropyridin-1-yl)phenyl]-4,5-dihydro-3(2H)-pyridazinone A mixture of (R)-6-(4-aminophenyl)-5-methyl-4,5-dihydro-3(2H)-pyridazinone (100 mg), 4H-pyran-4-one (52 mg) and hydrochloric acid (0.1N, 1 ml) in water (1.3 ml) was stirred under reflux under nitrogen for 3 hours. Aqueous ammonia (880, 0.01 ml) was added to the cooled reaction mixture to afford the title compound which was collected, washed with water and dried, 91 mg, m.p. 257-8 C. (softens 120 C.), [alpha]D25 =-369.5 (1.07% in dimethylformamide)., 36725-28-7

The synthetic route of 36725-28-7 has been constantly updated, and we look forward to future research findings.

Reference：
Patent; Smith Kline & French Laboratories Limited; US4906628; (1990); A;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.65632-62-4,(S)-1-((Benzyloxy)carbonyl)hexahydropyridazine-3-carboxylic acid,as a common compound, the synthetic route is as follows.,65632-62-4

The hexahydropyridazinic acid (40 g; 0.151 mol) is dissolved in 200 ml of methanol and cooled to 0 C. SOCl2 (36 ml; 0.45 mol) is added dropwise. The solution becomes clear; the temperature is allowed to return very gradually to ambient temperature, and the solution is then refluxed for one hour. The mixture is poured onto a DCM(200 ml)/ice(500 g) /NaHCO3(60 g) mixture. The aqueous phase is extracted with DCM. The organic phase is washed with a saturated NaHCO3 solution and then dried over MgSO4. A colorless oil is obtained (41 g; 99%) and is used as it is.

65632-62-4 (S)-1-((Benzyloxy)carbonyl)hexahydropyridazine-3-carboxylic acid 11129166, apyridazine compound, is more and more widely used in various fields.

Reference：
Patent; Aventis Pharma S.A.; US2005/215553; (2005); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

28682-68-0, 3,6-Dichloro-5-nitropyridazin-4-amine is a pyridazine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

The Pd/C (5%), 5 g) was added to the mixture of intermediate 1 1 (17 g, 81.7 mmol, 1 eq.) in MeOH (1000 ml). The solution was stirred overnight at 25C under the atmosphere of (50 psi). The catalyst was filtered through a diatomite pad. The solvent was removed under vacuum. (15 g, crude yield 100%) of intermediate 12 was isolated. Step 3 : synthesis of pyridazine-4,5-diamine 13 The potassium carbonate (22.6 g, 164 mmol, 2 eq.) was added to the mixture of intermediate 12 (15 g, 82 mmol, 1 eq.) in MeOH (150 ml) and CH2C12 (150 ml). The solution was stirred overnight at room temperature. The solution was filtered and the filtrate was concentrated under vacuum intermediate 13 was isolated (9 g, yield 95%>)., 28682-68-0

The synthetic route of 28682-68-0 has been constantly updated, and we look forward to future research findings.

Reference：
Patent; JANSSEN R&D IRELAND; TAHRI, Abdellah; JONCKERS, Tim Hugo Maria; RABOISSON, Pierre Jean-Marie Bernard; DEMIN, Samuel Dominique; WO2014/114776; (2014); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.147362-88-7,N-(6-Chloropyridazin-3-yl)pivalamide,as a common compound, the synthetic route is as follows.

A mixture of N-(6-chloro-3-pyridazinyl)-2,2-dimethylpropanamide (65.3 g; 305.6 mmol) and morpholine (538 mL; 6.1 mmol) was heated at 120 C for 24 hours. The mixture was cooled and evaporated. The residue was poured into cooled water, basified with K2CO3 powder and DCM was added. The organic layer was separated, dried over MgSOzi, filtered and evaporated to dryness. The residue was crystallized from Epsilon2Omicron. The precipitate was filtered and dried to afford 69.3 g (87%) of intermediate 58., 147362-88-7

As the paragraph descriping shows that 147362-88-7 is playing an increasingly important role.

Reference：
Patent; JANSSEN PHARMACEUTICA NV; MEVELLEC, Laurence, Anne; MEERPOEL, Lieven; COUPA, Sophie; PONCELET, Virginie, Sophie; PILATTE, Isabelle, Noelle, Constance; PASQUIER, Elisabeth, Therese, Jeanne; BERTHELOT, Didier, Jean-Claude; QUEROLLE, Olivier, Alexis, Georges; MEYER, Christophe; ANGIBAUD, Patrick, Rene; DEMESTRE, Christophe, Gabriel, Marcel; MERCEY, Guillaume, Jean, Maurice; (203 pag.)WO2016/97359; (2016); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.446273-59-2,3-Amino-4-bromo-6-chloropyridazine,as a common compound, the synthetic route is as follows.

4-bromo-6-chloro-pyridazin-3-amine (3.0 g, 14.4 mmol) and (0298) tetrakis(triphenylphosphine)palladium (1666 mg, 144 muiotaetaomicron) were suspended in THF (13.2 g) and a solution of zinc chloride in Me-THF (2.0 M, 9 mL, 18 mmol) was added. The reaction mixture was cooled to -5C and methyllithium in diethoxymethane (3.1 M, 11.6 mL, 36 mmol) was added. The reaction mixture was stirred at 45C for 4 hours. Sodium sulfate decahydrate (11.7 g, 36 mmol) was added at room temperature, the mixture was stirred 1.5 hours at 60C, diluted with water (100 mL) and after 30 minutes the precipitate was filtered off. The precipitate was dissolved in aqueous HC1 2M (100 mL) and ethyl acetate (140 mL). The biphasic system was filtered, the phases were separated and the pH of the water layer adjusted to 7 with aqueous NaOH 32% (18 mL). The precipitate was filtered and dried. The solid obtained was digested twice in methanol (20 mL) at room temperature. The two filtrates were combined, evaporated and dried under high vacuum to afford 6-chloro-4-methyl-pyridazin-3-amine (1.2 g, 58.1%) as a red solid. (0299) -NuMuRhonu (CDCb, 600 MHz): 7.09 (d, 1H); 4.90 (br s, 2H), 2.17 (d, 3H), 446273-59-2

446273-59-2 3-Amino-4-bromo-6-chloropyridazine 22024419, apyridazine compound, is more and more widely used in various fields.

Reference：
Patent; F. HOFFMANN-LA ROCHE AG; HOFFMANN-LA ROCHE INC.; ADAM, Jean-Michel; FANTASIA, Serena Maria; FISHLOCK, Daniel Vincent; HOFFMANN-EMERY, Fabienne; MOINE, Gerard; PFLEGER, Christophe; MOESSNER, Christian; (73 pag.)WO2019/57740; (2019); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.147362-88-7,N-(6-Chloropyridazin-3-yl)pivalamide,as a common compound, the synthetic route is as follows.

A flask was charged with N-(6-chloro-pyridazin-3-yl)-2,2-dimethyl-propionamide (Turck. Alain; PIe, Nelly; Ndzi, Bruno; Queguiner, Guy; Haider, Norbert Schuller, Herbert; Heinisch, Gottfried. Tetrahedron. 1993, 49, 599-606.) (500 mg, 2.34 mmol), Pd(PPh3)4 (811 mg, 0.701 mmol), and Zn(CN)2 (192 mg, 1.64 mmol) and placed under a nitrogen atmosphere. DMF (25 mL) was added to the flask and the reaction mixture was heated at 100 oC for 2.5 h. The reaction mixture was cooled and poured into H2O (100 mL) and EtOAc (100 mL), An emulsion formed and the mixture was filtered through a short plug of celite and then the layers were separated. The organic layer was washed with H2O (100 mL), dried (MgSO4), filtered, concentrated, and purified by chromatography (loaded with CH2CI2, eiuted with a gradient of 10-30% EtOAc in hexanes) to provide 329 mg of N-(6-cyano-pyridazin-3-yl)- 2,2-dimethyl-propionamde as a pale yellow solid. MS: (M+) 205. 1H NMR (400 MHz, CDCl3): delta 8.71 (bs, 1), 8.65 (d, 1, J = 9.3), 7.80 (d, 1, J = 9.3), 1.36 (s, 9)., 147362-88-7

The synthetic route of 147362-88-7 has been constantly updated, and we look forward to future research findings.

Reference：
Patent; PFIZER PRODUCTS INC.; WO2007/34278; (2007); A2;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

Chemical engineers work across a number of sectors, processes differ within each of these areas, but chemistry and chemical engineering roles are directly involved in the design, creation and manufacturing process of chemical products and materials. Safety of Methyl 3,6-dichloropyridazine-4-carboxylate

The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein A is A1, A2, A3 or A4 and R1, R2, R3, R4a, R4b, R5, R6, Ar, X1, X2, X4, X4 and X5 are as herein defined. Also disclosed in the present invention are methods of treating an HIV infection with compounds defined herein and pharmaceutical compositions containing said compounds. [image]

If you are interested in 286946-24-5, you can contact me at any time and look forward to more communication. Safety of Methyl 3,6-dichloropyridazine-4-carboxylate

Reference：
Pyridazine – Wikipedia,
Pyridazine | C4H4N2898 – PubChem

In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 187973-60-0, name is 6-Iodopyridazin-3-amine, introducing its new discovery. SDS of cas: 187973-60-0

Tumors have evolved a variety of methods to reprogram conventional metabolic pathways to favor their own nutritional needs, including glutaminolysis, the first step of which is the hydrolysis of glutamine to glutamate by the amidohydrolase glutaminase 1 (GLS1). A GLS1 inhibitor could potentially target certain cancers by blocking the tumor cell’s ability to produce glutamine-derived nutrients. Starting from the known GLS1 inhibitor bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide, we describe the medicinal chemistry evolution of a series from lipophilic inhibitors with suboptimal physicochemical and pharmacokinetic properties to cell potent examples with reduced molecular weight and lipophilicity, leading to compounds with greatly improved oral exposure that demonstrate in vivo target engagement accompanied by activity in relevant disease models.

I hope this article can help some friends in scientific research. I am very proud of our efforts over the past few months and hope to 187973-60-0, help many people in the next few years.SDS of cas: 187973-60-0

Reference：
Pyridazine – Wikipedia,
Pyridazine | C4H4N2943 – PubChem

In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 34127-22-5, name is Ethyl 3,6-dichloropyridazine-4-carboxylate, introducing its new discovery. SDS of cas: 34127-22-5

Leucine-rich repeat kinase 2 (LRRK2) has been implicated in the pathogenesis of Parkinson’s disease (PD). Inhibition of LRRK2 kinase activity is a therapeutic approach that may lead to new treatments for PD. Herein we report the discovery of a series of [1,2,4]triazolo[4,3-b]pyridazines that are potent against both wild-type and mutant LRRK2 kinase activity in biochemical assays and show an unprecedented selectivity towards the G2019S mutant. A structural rational for the observed selectivity is proposed.

I hope this article can help some friends in scientific research. I am very proud of our efforts over the past few months and hope to 34127-22-5, help many people in the next few years.SDS of cas: 34127-22-5

Reference：
Pyridazine – Wikipedia,
Pyridazine | C4H4N2958 – PubChem

Quality Control of 4,5-Dibromopyridazin-3(2H)-one, The dynamic chemical diversity of the numerous elements, ions and molecules that constitute the basis of life provides wide challenges and opportunities for research.

A 3(2H)pyridazinone of the formula: STR1 wherein R1 is hydrogen, methyl, C3 -C6 alkenyl, C5 or C6 cycloalkyl, benzyl, phenyl, –(CH2)m CO2 R3 (wherein R3 is hydrogen or C1 -C5 alkyl, and m is an integer of from 1 to 4), –(CH2)n A (wherein A is –OH or –N(R4)2 wherein R4 is C1 -C3 alkyl, and n is an integer of from 2 to 6) or –CH2 CF3 ; R2 is chlorine or bromine; each of Y1 and Y2 which may be the same or different, is hydrogen, C1 -C5 alkyl, C2 -C8 alkenyl, halogen, –OR5 (wherein R5 is hydrogen, C1 -C8 alkyl or STR2 wherein q is an integer of from 1 to 4), –CO2 R6 (wherein R6 is hydrogen or C1 -C5 alkyl), –N(R7)2 (wherein R7 is C1 -C4 alkyl) or –SR8 (wherein R8 is C1 -C4 alkyl); and Y3 is C1 -C5 alkyl, C2 -C8 alkenyl, halogen, –OR5 (wherein R5 is as defined above), –CO2 R6 (wherein R6 is as defined above), –N(R7)2 (wherein R7 is as defined above) or –SR8 (wherein R8 is as defined above), or a pharmaceutically acceptable salt thereof.

Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.Quality Control of 4,5-Dibromopyridazin-3(2H)-one. In my other articles, you can also check out more blogs about 5788-58-9

Reference：
Pyridazine – Wikipedia,
Pyridazine | C4H4N3153 – PubChem